Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins

References

• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.
   PubMed Web of Science ®Google Scholar
• Scott SC, Lee SS, Abraham J. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. Semin Oncol. 2017;44(6):385–394. doi: 10.1053/j.seminoncol.2018.01.006.
   PubMed Web of Science ®Google Scholar
• Kim ES, Scott LJ. Palbociclib: a review in HR-positive, HER2-negative, advanced or metastatic breast cancer. Target Oncol. 2017;12(3):373–383. doi: 10.1007/s11523-017-0492-7.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Metzger-Filho O. Novel strategies in hormone receptor-positive advanced breast cancer: overcoming endocrine resistance. Curr Breast Cancer Rep. 2016;8(4):193–205. doi: 10.1007/s12609-016-0228-1.
   Google Scholar
• Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–292. doi: 10.1002/path.1706.
   PubMed Web of Science ®Google Scholar
• Kazan HH, Urfali-Mamatoglu C, Gunduz U. Iron metabolism and drug resistance in cancer. Biometals. 2017;30(5):629–641. doi: 10.1007/s10534-017-0037-7.
   PubMed Web of Science ®Google Scholar
• Urfali-Mamatoglu C, Kazan HH, Gündüz U. Dual function of programmed cell death 10 (PDCD10) in drug resistance. Biomed Pharmacother. 2018;101:129–136. doi: 10.1016/j.biopha.2018.02.020.
   PubMed Web of Science ®Google Scholar
• Kazan HH, Urfali‐Mamatoglu C, Yalcin GD, et al. 15‐LOX‐1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin. J Cell Physiol. 2020;235(5):4965–4978. doi: 10.1002/jcp.29375.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol. 1997;160(3):161–175. doi: 10.1007/s002329900305.
   PubMed Web of Science ®Google Scholar
• Işeri OD, Kars MD, Arpaci F, et al. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol. 2010;65(3):447–455. doi: 10.1007/s00280-009-1048-z.
   PubMed Web of Science ®Google Scholar
• Kars MD, Işeri OD, Ural AU, et al. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res. 2007;27(6B):4031–4037. PMID:18225567
   PubMed Web of Science ®Google Scholar
• Nie H, Zhou X, Shuzhang D, et al. Palbociclib overcomes afatinib resistance in non-small cell lung cancer. Biomed Pharmacother. 2019;109:1750–1757. doi: 10.1016/j.biopha.2018.10.170.
   PubMed Web of Science ®Google Scholar
• De Gooijer MC, Zhang P, Thota N, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs. 2015;33(5):1012–1019. doi: 10.1007/s10637-015-0266-y.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Gholam MH, Hashemi F, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discov Today. 2022;27(2):436–455. doi: 10.1016/j.drudis.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Robinson K, Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol. 2020;10:265. doi: 10.3389/fonc.2020.00265.
   PubMed Web of Science ®Google Scholar
• Baran Y, Salas A, Senkal CE, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007;282(15):10922–10934. doi: 10.1074/jbc.M610157200.
   PubMed Web of Science ®Google Scholar
• Kars MD, Iseri ÖD, Ural AU, et al. Development of radioresistance in drug resistant human MCF-7 breast cancer cells. J Radiother Pract. 2009;8(4):207–213. doi: 10.1017/S1460396909990070.
   Google Scholar
• Mutlu P, Azarkan SY, Pourianazar NT, et al. Determination of the relationship between doxorubicin resistance and WNT signaling pathway in HeLa and K562 cell lines. EXCLI Journal. 2018;17:386. 10.17179/excli2018-1129
   PubMed Web of Science ®Google Scholar
• Kars MD, Iseri OD, Gündüz U, et al. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006;26(6B):4559–4568. PMID:17201178
   PubMed Web of Science ®Google Scholar
• Duan C, Liu W, Tao Y, et al. Two novel palbociclib-resorcinol and palbociclib-orcinol cocrystals with enhanced solubility and dissolution rate. Pharmaceutics. 2021;14(1):23. doi: 10.3390/pharmaceutics14010023.
   PubMed Web of Science ®Google Scholar
• Cook Sangar ML, Genovesi LA, Nakamoto MW, et al. Inhibition of CDK4/6 by palbociclib significantly extends survival in medulloblastoma patient-derived xenograft mouse models. Clin Cancer Res. 2017;23(19):5802–5813. doi: 10.1158/1078-0432.CCR-16-2943.
   PubMed Web of Science ®Google Scholar
• Saleh L, Ottewell PD, Brown JE, et al. The CDK4/6 inhibitor palbociclib inhibits estrogen-positive and triple negative breast cancer bone metastasis in vivo. Cancers (Basel). 2023;15(8):2211. doi: 10.3390/cancers15082211.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866–2868. doi: 10.1093/bioinformatics/btw230.
   PubMed Web of Science ®Google Scholar
• Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93–141.
   PubMed Web of Science ®Google Scholar
• Francis AM, Alexander A, Liu Y, et al. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell-cycle arrest. Mol Cancer Ther. 2017;16(9):1751–1764. doi: 10.1158/1535-7163.
   PubMed Web of Science ®Google Scholar
• Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol. 2013;3:290. doi: 10.3389/fonc.2013.00290.
   PubMedGoogle Scholar
• Valko Z, Megyesfalvi Z, Schwendenwein A, et al. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. Br J Cancer. 2023;128(10):1850–1861. doi: 10.1038/s41416-023-02219-9.
   PubMed Web of Science ®Google Scholar
• Solta A, Boettiger K, Kovács I, et al. Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair. Clin Cancer Res. 2023;29(22):4644–4659. doi: 10.1158/1078-0432.CCR-23-1795.
   PubMed Web of Science ®Google Scholar
• Zingales V, Fedeli C, Fernández-Franzón M, et al. Cytotoxic effects of individual and combined sterigmatocystin and nivalenol on liver hepatocellular carcinoma cells. Food Chem Toxicol. 2020;143:111473. doi: 10.1016/j.fct.2020.111473.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Montazeri H, Tarighi P. Synergistic anti-tumor effects of liraglutide, a glucagon-like peptide-1 receptor agonist, along with docetaxel on LNCaP prostate cancer cell line. Eur J Pharmacol. 2020;878:173102. doi: 10.1016/j.ejphar.2020.173102.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Palbociclib: first global approval. Drugs. 2015;75(5):543–551. doi: 10.1007/s40265-015-0379-9.
   PubMed Web of Science ®Google Scholar
• Wu T, Chen Z, To KK, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017;124:29–42. doi: 10.1016/j.bcp.2016.10.015.
   PubMed Web of Science ®Google Scholar
• Sorf A, Sucha S, Morell A, et al. Targeting pharmacokinetic drug resistance in acute myeloid leukemia cells with CDK4/6 inhibitors. Cancers (Basel). 2020;12(6):1596. doi: 10.3390/cancers12061596.
   PubMed Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53(1):615–627. doi: 10.1146/annurev.med.53.082901.1039294.
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837. doi: 10.1007/s10637-014-0120-7.
   PubMed Web of Science ®Google Scholar
• Gupta P, Zhang YK, Zhang XY, et al. Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells. Cell Physiol Biochem. 2018;45(4):1515–1528. doi: 10.1159/000487578.
   PubMedGoogle Scholar
• Juvale IIA, Hamid AAA, Abd Halim KB, et al. P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon. 2022;8(6):e09777. doi: 10.1016/j.heliyon.2022.e09777.
   PubMed Web of Science ®Google Scholar
• Blais A, Dynlacht BD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev. 2004;14(5):527–532. doi: 10.1016/j.gde.2004.07.003.
   PubMed Web of Science ®Google Scholar
• Yan LH, Wei WY, Cao WL, et al. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance. BMC Cancer. 2014;14(1):904. doi: 10.1186/1471-2407-14-904.
   PubMedGoogle Scholar
• Zhao G. Reversal effect of palbociclib on the resistance of breast cancer MCF-7 cells to doxorubicin. Tumor. 2017;37(8):831–839. doi: 10.3781/j.issn.1000-7431.2017.11.191.
   Google Scholar
• Han L, Wang Y, Guo X, et al. Downregulation of MDR1 gene by cepharanthine hydrochloride is related to the activation of c-Jun/JNK in K562/ADR cells. Biomed Res Int. 2016;4729643. doi: 10.1155/2016/4729643.
   PubMed Web of Science ®Google Scholar
• Corrêa S, Binato R, Du Rocher B, et al. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012;12(1):303. doi: 10.1186/1471-2407-12-303.
   PubMedGoogle Scholar